GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Grifols SA (XMAD:GRF) » Definitions » Price-to-Owner-Earnings

Grifols (XMAD:GRF) Price-to-Owner-Earnings

: (As of Today)
View and export this data going back to 2006. Start your Free Trial

As of today (2024-04-19), Grifols's share price is €8.346. Grifols does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Grifols's Price-to-Owner-Earnings or its related term are showing as below:

During the past 13 years, the highest Price-to-Owner-Earnings of Grifols was 180.90. The lowest was 17.75. And the median was 32.94.


XMAD:GRF's Price-to-Owner-Earnings is not ranked *
in the Drug Manufacturers industry.
Industry Median: 27.51
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-04-19), Grifols's share price is €8.346. Grifols's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 was €0.26. Therefore, Grifols's PE Ratio for today is 32.35.

As of today (2024-04-19), Grifols's share price is €8.346. Grifols's EPS without NRI for the trailing twelve months (TTM) ended in was €0.17. Therefore, Grifols's PE Ratio without NRI for today is 49.98.

During the past 13 years, Grifols's highest PE Ratio without NRI was 621.17. The lowest was 15.81. And the median was 28.90.


Grifols Price-to-Owner-Earnings Historical Data

The historical data trend for Grifols's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Grifols Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 166.30 21.28 - - -

Grifols Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Dec21 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23
Price-to-Owner-Earnings Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison

For the Drug Manufacturers - General subindustry, Grifols's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Grifols Price-to-Owner-Earnings Distribution

For the Drug Manufacturers industry and Healthcare sector, Grifols's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Grifols's Price-to-Owner-Earnings falls into.



Grifols Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Grifols's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=8.346/-0.20
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Grifols  (XMAD:GRF) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Grifols Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Grifols's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Grifols (XMAD:GRF) Business Description

Address
Avinguda de la Generalitat, 152-158, Parc de Negocis Can Sant Joan, Sant Cugat del Valles, Barcelona, ESP, 08174
As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and the firm's biopharma business contributed 83% of sales in 2022. Grifols also has smaller segments including diagnostics and biosupplies. Diagnostics is roughly 10% of revenue following the Biotest acquisition.